{"id":"ckd-342","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vaginal dryness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CKD-342 functions as a SERD by binding to the estrogen receptor with high affinity and promoting its proteasomal degradation, thereby eliminating both ligand-dependent and ligand-independent estrogen receptor signaling. This mechanism is distinct from selective estrogen receptor modulators (SERMs) and provides more complete suppression of estrogen receptor activity. The drug is being developed for hormone receptor-positive breast cancer and other estrogen-dependent malignancies.","oneSentence":"CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:11.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT02498509","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of CKD-342","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2015-05","conditions":"Rhinitis, Allergic, Perennial","enrollment":459}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["investigational product"],"phase":"phase_3","status":"active","brandName":"CKD-342","genericName":"CKD-342","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CKD-342 is a selective estrogen receptor degrader (SERD) that binds to and degrades estrogen receptors, blocking estrogen-dependent signaling in hormone-sensitive cancers. Used for Hormone receptor-positive, HER2-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}